Skip to main content

View most popular

Social Links

  • Search
  • Twitter
  • LinkedIn

Header top menu

  • About Us
  • Contact

Members

  • Create new Account
  • Subscribe
  • Log in
Home

Main navigation

  • Sections
    • BioPharma
    • Medicine
    • Patients
    • Payers
    • Politics
    • Research
  • Topics
    • access+affordability
    • global+growth
    • evaluations+economics
    • technology+therapeutics
    • policy+practice
  • Regions
    • Africa
    • Asia - Central
    • Asia - East
    • Asia - South
    • Asia-West / Mid-East / North-Africa
    • Europe
    • Global
    • North America
    • South America
    • South Pacific
  • Videos
  • Reports
  • Resources
    • Archives
    • Events
    • Links
    • Newsletter archive

EU Ends First Pharmaceutical Excessive Pricing Probe

@EU_Commission Feb 10, 2021

Bookmark this
Commission accepts commitments by Aspen to reduce prices for six off-patent cancer medicines by 73% addressing excessive pricing concerns

EU Ends First Pharmaceutical Excessive Pricing Probe

@EU_Commission Feb 10, 2021

Visit This Website

Comments

No comments yet. Create an account and log in to post a comment.

Subscribe by email

Follow Us:

  • Search
  • Twitter
  • LinkedIn
Home

News & Intelligence on BioPharmaceutical Pricing & Access

Footer

  • About Us
  • Contact

Created by Heat Informatics © 2016-2021
Web development by Woolwich Web Works

Join Us

It looks like you're enjoying the content on Heat Informatics. 

  • Join the Community
  • Get the Newsletter